TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Rhea-AI Summary
TuHURA Biosciences (Nasdaq: HURA), a Phase 3 registration-stage immune-oncology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. Dr. James Bianco, President and CEO of TuHURA, was part of the Precision and Immune Oncology panel. The company focuses on developing novel technologies to overcome resistance to cancer immunotherapy. A webcast replay of the panel presentation is available for M-Vest members.
Positive
- TuHURA's participation in a high-profile healthcare summit may increase visibility and investor interest.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, HURA declined 3.10%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
TAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. (Nasdaq:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC.
As part of the event, Dr. James Bianco, President and Chief Executive Officer of TuHURA participated in the Precision and Immune Oncology panel. To access the webcast replay, sign up to become anM-Vest member.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Investor Contact:
Jenene Thomas
JTC Team, LLC
908.824.0775
tuhura@jtcir.com
SOURCE: TuHURA Biosciences, Inc.
View the original press release on accesswire.com
FAQ
What event did TuHURA Biosciences participate in?
Who represented TuHURA at the 2024 Maxim Healthcare Virtual Summit?
What was the focus of TuHURA Biosciences' panel at the summit?
How can one access the webcast replay of TuHURA's panel presentation?
